Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL)
Completed
ADC Therapeutics S.A.
Phase 1
2016-03-01
This study evaluates ADCT-402 in participants with Relapsed or Refractory B-cell Lineage Non
Hodgkin Lymphoma (B-NHL). Participants will participate in a dose escalation phase (Part 1)
and dose expansion (Part 2). In Part 2, participants will receive the dose level identified
in Part 1.
Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL)
Completed
ADC Therapeutics SARL
Phase 1
2016-03-01
This study evaluates ADCT-402 in participants with Relapsed or Refractory B-cell Lineage Non
Hodgkin Lymphoma (B-NHL). Participants will participate in a dose escalation phase (Part 1)
and dose expansion (Part 2). In Part 2, participants will receive the dose level identified
in Part 1.
Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)
Terminated
ADC Therapeutics S.A.
Phase 1
2016-03-01
This study evaluates ADCT-402 in participants with relapsed or refractory B-cell lineage
acute lymphoblastic leukemia (B-ALL). Participants will participate in a dose-escalation
phase (Part 1) and dose expansion (Part 2). In Part 2, participants will receive the dose
level identified in Part 1.
Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)
Terminated
ADC Therapeutics SARL
Phase 1
2016-03-01
This study evaluates ADCT-402 in participants with relapsed or refractory B-cell lineage
acute lymphoblastic leukemia (B-ALL). Participants will participate in a dose-escalation
phase (Part 1) and dose expansion (Part 2). In Part 2, participants will receive the dose
level identified in Part 1.
Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Active, not recruiting
ADC Therapeutics S.A.
Phase 2
2018-08-01
The purpose of this Phase 2 study is to evaluate the clinical efficacy and safety of
Loncastuximab Tesirine (ADCT-402) in patients with relapsed or refractory Diffuse Large
B-Cell Lymphoma.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
